Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Medical Solutions LSE:AMS London Ordinary Share GB0004536594 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.75p -0.56% 313.50p 313.50p 314.25p 316.25p 312.00p 314.50p 186,819 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 82.6 19.1 7.5 41.9 655.45

Advanced Medical Solutions (AMS) Latest News

More Advanced Medical Solutions News
Advanced Medical Solutions Takeover Rumours

Advanced Medical Solutions (AMS) Share Charts

1 Year Advanced Medical Solutions Chart

1 Year Advanced Medical Solutions Chart

1 Month Advanced Medical Solutions Chart

1 Month Advanced Medical Solutions Chart

Intraday Advanced Medical Solutions Chart

Intraday Advanced Medical Solutions Chart

Advanced Medical Solutions (AMS) Discussions and Chat

Advanced Medical Solutions Forums and Chat

Date Time Title Posts
20/6/201714:59Advanced Medical Solutions (AMS)2,837
19/10/201208:53AMS (Advanced Medical Systems). The next BULL stock.3,430
20/2/200909:39STRONG BUY !!!!!! ADVANCED MEDICAL412
20/2/200909:35Got wood?190
20/2/200909:33AMS ..Undervalued????????6

Add a New Thread

Advanced Medical Solutions (AMS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-08-18 16:08:04313.95145455.23O
2017-08-18 16:04:57313.88255800.40O
2017-08-18 16:04:10314.00140439.60O
2017-08-18 16:02:45313.091,2003,757.07O
2017-08-18 15:55:44313.2563197.35O
View all Advanced Medical Solutions trades in real-time

Advanced Medical Solutions (AMS) Top Chat Posts

Advanced Medical Solutions Daily Update: Advanced Medical Solutions is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AMS. The last closing price for Advanced Medical Solutions was 315.25p.
Advanced Medical Solutions has a 4 week average price of 290.50p and a 12 week average price of 273.75p.
The 1 year high share price is 317p while the 1 year low share price is currently 198.50p.
There are currently 209,075,180 shares in issue and the average daily traded volume is 333,673 shares. The market capitalisation of Advanced Medical Solutions is £655,450,689.30.
jeffcranbounre: Advanced Medical Solutions is featured in today's ADVFN podcast. To listen to the podcast click here> In today's podcast: - Chris Oil, financial writer and city investor will be chatting about a well known name who could be back in fashion. Chris on Twitter is @ChrisOil - And Rodney Hobson, a financial speaker, writer and author of investment books including Shares Made Simple, the beginner's guide to the stock market. Rodney on Twitter is @RodneyHobson - The micro and macro news - Plus the broker forecasts Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below. Ten Bagger Tuesday (All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below: Suggest a stock (Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). You can subscribe to this podcast in iTunes by clicking HERE To follow me on Twitter click HERE As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions: Bronze - £50 (normally £73.82/year) Silver - £145 (normally £173.71/year) Level 2 - £350 (normally £472.94/year) Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just CLICK HERE for more information. Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing. Justin    
jmf69: Potential for upside with Advanced Medical Solutions Advanced Medical Solutions (AMSU) may have underperformed the FTSE All-Share but Investec believes there is potential for upside. Analyst Cora McCallun retained her 'add' rating and target price of 129p on the shares after the company published a brief trading statement prior to results for the first half of its financial year. Shares were trading at 110.1p at yesterday's close. 'The company confirms that the business is on track to meet current market expectations for both full-year 2014 revenue and profitability,' she said. 'Only the bulk materials division performed below expectations, but this has been compensated by stronger growth elsewhere. 'Given the recent share price movement, underperforming the FTSE All Share by around 10% over the second quarter, we believe the stock offers material upside with potential for upgrades.'
lozler: Haha, will be good news when it comes though, especially with the directors buying in at a much higher price than the current share price. Happy to hold.
apad: I suppose it'll need IC or whatever to move the share price on product news. Better performance in Germany needed to cause a sea change. Bought some more yesterday - I get a glow from not paying the government when buying AIM shares. Thanks for keeping the thread alive JMF. apad
dealit: Norbus thank you for the reply. Nice to see Octopus increasing at this share price
pedr01: Someone is going to take AMS out but when?????? If it happens, I think it would be a shame actually ... Don't understand why majority UK investors won't let their companies grow and always want to be taken over for a tiny up-lift in share price ...
waggle: see below from Panmure Advanced Medical Solutions: Stick with this one Recommendation - Buy Analyst - Dr Mike Mitchell +44 (0)207 886 2761 AMS has an established track record as an innovator in global woundcare and wound closure markets. The 2011 acquisition of RESORBA widened the company's geographic footprint. While increased European exposure increased sales volatility we believe this is already in the share price and consider the positioning remains attractive. We initiate with Buy, using an in-line sector rating to derive a target price of 90p.
cgequityinvest: Sorry for delay in posting but here is my summary of key points from analyst's meeting following release of interims last week. Interims *Sales up 47% (v H1 2009) to £14.5m. However these included £2.2m of turnover from the Corpura acquisition so on a like for like basis sales up 25%. *Gross margin reduced from 49% to 46%. At first sight disappointing but it reflects a combination of factors including the Corpura sales which are at lower margin, some dual running of manufacturing (as they finalise factory move) and product mix. Mgment expect margin to fully recover once the factory move is complete and they start to get efficiencies. *Exceptional costs of £644k relating to the factory move. *PBT pre exceptional s up from £925k (eps of 0.64) to £2,132k (eps of 1.42). *The increase in earnings is pretty spectacular but one needs to remember that the corresponding period in 2009 was a more difficult half for AMS when they were hit by destocking. The operational gearing is a positive point with operating expenses down to 31% of sales against 39% in previous half and 33% for the whole of last year. Cash Cash generation was not as strong as I expected given EBITDA of £2.8m which was swallowed up by £2m of cap ex (largely on factory) £0.7m on Corpura acquisition and £1.6m on working capital. However the FD explained that the working capital usage was inflated by a slight delay on two large debtor payments totalling £0.6m which were received within 3 days of half year end. Looking ahead if you strip out the acquisition and factory cap ex and assume a normalised level (say £0.5m on other cap ex) then the business shows it can chuck off the cash hence its ability to cover dividends in the future. Outlook for full year At the last analyst meeting (April) the FD advised an anticipated 45% first half / 55% second half expected split in sales for 2010. This time round she said that the split will be more even. Based on this I reckon they will end up with turnover just above £30m and a PBT somewhere around £5.1m giving eps of 3.5/3.6. This is pretty much in line with forecasts and would represent earnings growth of between 20 and 25% on 2009. In past years AMS have earned circa £500k per year from R & D subsidised by partners – in the first half this was nil – I have emailed the FD asking for feedback on anticipated levels in the second half – this could impact upon the above figures. Other points made in presentation *There has been some slowdown in market growth rates which they now estimate to be growing at between 5 and 10% - however AMS continue to grab market share. *The growth in their silver alginate woundcare dressing sales to £4m in first half has elevated them to number two market share (20%) globally behind Aquacel and they believe they can continue to gain market share through product quality. At present AMS price is 10% below Aquacel's core product. * Mgment are optimistic regarding progress to date re the recent launch of Liquiband into the US wound closure market – see below for further details. *Further distribution developments – mgment have located a partner in Japan but the market is modest. They are currently looking for distribution partners in Canada and also evaluating the Far East and South American markets. * Following the launch of Liquiband in the US, mgment stressed the increasing importance of their proprietary brands (Liquiband and Activeheal) and will be seeking to support the brands via increased marketing spend. *R & D expenditure will probably be circa 6% of turnover this year – similar in absolute numbers to last year but lower in percentage terms. However , brand marketing will increase. *A key focus for R & D remains development of technologies (in addition to silver) that accelerate wound healing. *AMS expect to have their first product in the internal adhesive market ready for the market in 2011, via a hernia focused product for which they will initially seek European approval. *The new premises are expected to be finished and fully operational by the end of this year - exceptional costs relating to the move will total £1m for the year (both in line with previous projections). Liquiband progress For those new to AMS, Liquiband is an adhesive used to close wounds – see for further details. AMS dominate the market in the UK but market size is worth a modest £4m. Over the past two years AMS have sought to get approval to launch in the US where the market is worth an estimated $210m. The market leader in the US is Dermabond which has a 95% share. Following approval AMS launched their products earlier this year via distributors. They now have four distribution partners including Cardinal. Feedback on Liquiband included: •The Liquiband product is technically superior to Dermabond – the latter has a longer setting time and requires two applications. •Dermabond has two products a straight ampoule (a syringe type application) and Propen which is the ampoule fitted in an applicator. Dermabond has responded in the market by seeking to encourage customers to use the cheaper ampoule product as opposed to any price cutting. However AMS products are still $4 cheaper than the ampoule. •At present Cardinal have 200 Liquiband evaluations being underway in the acute care market (hospitals). The overall acute care market in the US is 3000 hospitals. Feedback is partially anecdotal but AMS are "very encouraged". They will get a better feel for take up when they get third quarter and fourth quarter sales figures. •AMS have recently appointed McKesson to target the surgery markets in the US. This represents 20% of the US market (acute is 80%). •At some stage AMS expect Dermabond to react with some form of R&D improvement – no timescale was given but my guess would be this will take time (unless they already have developments in train). •As commented AMS will be looking to support Liquiband via brand marketing. Longer term outlook Following today's price rise to 57.5p the current year P/E (based on eps of 3.6) is 16. I think the chances of them materially exceeding the 3.5/3.6 are relatively limited. The forecast dividend payments next year may attract some new inst shareholders. To my mind the longer term prospects and quality of the business model remain pretty strong. Their markets are still growing at between 5 and 10%, the company currently has technically superior products and a good R & D pipeline. They are cash generative, have negligible debt and have (in my view) a strong, settled exec team. There are plenty of new markets for them to attack both geographically and via new product development. Downsides – market growth is slowing a bit from previous double digit growth and they are now competing directly against some big competitors who could turn aggressive (or of course seek to buy them!) 2011 forecasts are based on average of £6.4m PBT and 4.3 eps. I think there is some potential upside here based on some margin recovery, the operational gearing and the potential for Liquiband in the US. However just hitting their forecasts represents 20% earnings growth. As ever DYOR Disclosure – I have been a shareholder in AMS for five years. If anybody has specific questions pls advise and I will try to cover.
dealit: AMS share price seems to move north on small share buying, not a lot of shares about perhaps.
substp: More important Norbus ..... :-) "It said it was reserving the right to make an offer for AMS within 6 months if a third party makes an approach or if it gets the agreement of the AMS board. Charles Weston, an analyst at Nomura Code, has told Crain's that the AMS share price could rise as high as 58p if the group's LiquiBand product gains traction in the USA."
Advanced Medical Solutions share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170819 07:08:19